Seeking Alpha

Novavax (NVAX): Q4 EPS of -$0.06 misses by $0.01. Revenue of $4.56M misses by $2.48M. (PR)

Novavax (NVAX): Q4 EPS of -$0.06 misses by $0.01. Revenue of $4.56M misses by $2.48M. (PR)
Comments (1)
  • Clinical Stage BioPharma............e... are irrelevant. Pipeline & Cash are most important. Great advancements on both fronts. Share price will climb. Company positioning itself for future success. Buy in dips.
    1 Mar 2013, 08:37 AM Reply Like
DJIA (DIA) S&P 500 (SPY)